Study was stopped due to non-enrollment of subjects due to rarity of disease.

The protocol is designed for the compassionate treatment of patients with Fanconi Anemia who do not have an HLA-matched sibling donor. The purpose of this study is to determine the likelihood of engraftment in Fanconi Anemia patients using total body irradiation (TBI), cyclophosphamide (CY), fludarabine (FLU) and antithymocyte globulin (ATG) followed by an unrelated donor hematopoietic cell transplant with T-cell depletion using the CliniMACS device.

The major obstacle to successful alternate donor HCT for patients with Fanconi Anemia is graft failure. While T-cell depletion decreases the incidence of aGVHD, its effect on improving long term survival is unproven. To potentially improve engraftment rate, we have chosen a relatively new immunosuppressive agent, fludarabine (FLU), FLU is an antineoplastic agent that has been shown to be an effective immunosuppressive agen in BMT conditioning therapy. The addition of FLU to the commonly used preparative regimen of CY and TBU in Fanconi Anemia patients may improve engraftment rates.

Based on all presented data and its outcome, hematopoietic stem cell transplantation with the use of total body irradiation (450 cGy), cyclophosphamide (10 mg/kg IV) and fludarabine (35 mg/m2 IV) as preparative cytoreductive therapy has become the standard treatment for the hematologic manifestations of Fanconi Anemia at CHLA. However, the use of Isolex 300i will be replaced by CliniMACS in processing T-cell depletion.

The CliniMACS CD34 Reagent System is an investigational medical device that has not yet been approved by the FDA. This device is used in vitro to select and enrich specific cell populations. When using the CliniMACS CD34 Reagent, the system selects CD34+ cells from heterogenous hematological cell populations for transplantation in cases where this is clinically indicated. Based on the gathered data, CliniMACS has not been a contributing factor in the toxicity of patients, although may have a potential of eliciting "antibody" reactions in some patients, the process has been of significant life-saving benefit as compared to the potential risks.

Inclusion Criteria:

• Patients must be > 2 months and < 21 years of age with a diagnosis of Fanconi anemia.

• Patients must have an HLA-A, B, DRB1 identical or 1 antigen mismatched related (non-sibling) or unrelated donor. Patients and donors will be typed for HLA-A and B using serological or molecular techniques and for DRB1 using high resolution molecular typing. (Patients with a 2 antigen mismatched related donor will be eligible for the protocol but evaluated separately).

• Patients with FA must have high risk genotype or aplastic anemia (AA) or myelodysplastic syndrome without excess blasts.

• Aplastic anemia is defined as having at least one of the following:

  1. platelet count <20 x 109/L
  2. ANC <5 x 108/L
  3. Hgb <8 g/dL with at least one of the following:
  1. transfusion dependence
  2. supportive care toxicity

• Myelodysplastic syndrome with multilineage dysplasia with or without chromosomal anomalies.

• High risk genotype (e.g. IVS-4 or exon 14 FANCC mutations)

• Adequate major organ function including:

• Cardiac: ejection fraction >45%

• Renal: creatinine clearance >40 mL/min.

• Hepatic: no clinical evidence of hepatic failure (e.g. coagulopathy, ascites)

• Karnofsky performance status >70% or Lansky >50%

• Women of child bearing age must be using adequate birth control and have a negative pregnancy test.

Exclusion Criteria:

• Available HLA-genotypically identical related donor.
• The harvested marrow (prior to TCD) should contain a minimum of 2.5 x 108 nucleated cells/kg recipient body weight with a goal of >5.0 x 108 nucleated cells/kg recipient body weight.
• Positive lymphocytotoxic crossmatch against donor (T cells and B cells)
• History of gram negative sepsis or systemic fungal infection (proven or suspected based on radiographic studies).
• Myelodysplastic syndrome with excess blasts or leukemia.
• Active CNS leukemia at time of HCT.
• Malignant solid tumor (e.g. squamous cell carcinoma of the head/neck/cervix) within 2 years of HCT.
• Pregnant or lactating female.
• Prior radiation therapy preventing use of TBI 450 cGy.

Procedure as well as de-identified data is reported to CIBMTR and is available to other researchers.

End of subject enrollment and following 2 year subject follow-up

Researchers/Investigators interested in severe combined immune deficiency disease treatment and outcomes.